Mecanismos de Selectividad en Peptidos
Categorías: Metodología de Investigación, Información General
La selectividad es critica para seguridad terapeutica. Lograr alta selectividad requiere comprension de mecanismos moleculares.
Resumen Simplificado
Diferencias estructurales, sitios alostericos y optimizacion de farmacoforos crean selectividad.
Importancia de selectividad
Selectividad es seguridad. Problem. Off-target binding. Unintended effects. Side effects. Toxicity. Examples. Receptor subtypes. 5-HT receptor family. Many subtypes. Cross-reactivity. Serotonin syndrome. Kinase inhibitors. Kinome-wide activity. Cardiac toxicity. Ion channels. hERG block. Arrhythmia. Therapeutic window. Ratio of toxic dose to effective dose. Wider is better. Selectivity widens window. Regulatory focus. Safety pharmacology. Required studies. ICH S7A. S7B. Cardiovascular. CNS. Respiratory. Competitive advantage. Cleaner profile. Better tolerability. Market differentiation. Selectivity is not absolute. Relative concept. Fold-selectivity. Over relevant off-targets. Clinical context matters. Some off-targets tolerable. Others unacceptable. Know your liabilities.
Bases estructurales
Selectividad viene de estructura. Target differences. Sequence variation. Binding site differences. Subtle changes. Major differences. Structural analysis. Compare targets. Identify unique features. Opportunities for selectivity. Types of differences. Residue substitutions. Size change. Charge change. Polarity change. Structural features. Loop conformations. Pocket depth. Shape variations. Water networks. Different patterns. Exploiting differences. Design interactions. Match target only. Clash with off-target. Steric exclusion. Bulky groups. Fit target pocket. Too big for off-target. Electrostatic steering. Complementary charges. Wrong for off-target. Hydrogen bonding. Unique patterns. Only target has correct geometry. Structure enables selectivity. Understand differences. Design accordingly.
Selectividad por sitio alosterico
Allosteric sites offer selectivity. Advantages. Less conserved. Than orthosteric sites. Evolutionary pressure lower. More variability. Unique pockets. Target-specific. Selectivity inherent. Mechanism. Bind different site. Modulate activity. Not compete with endogenous. Types. PAMs. Positive modulators. Enhance response. NAMs. Negative modulators. Reduce response. Silent modulators. Occupy only. Design. Identify allosteric site. Structural studies. NMR. X-ray. Computational. Design binder. Not orthosteric. Examples. GPCR allosteric modulators. Highly selective. Kinase allosteric inhibitors. Type II, III. More selective than ATP-competitive. Ion channel modulators. Gating modifiers. Subtype-specific. Allosteric approach. Different strategy. Higher selectivity potential. Also different pharmacology. Not always applicable. Site must exist. Druggable.
Optimizacion de farmacoforo
Pharmacophore refinamiento mejora selectividad. Analysis. Active conformation. Critical features. Distance constraints. Target vs off-target. Compare pharmacophores. Identify differences. Unique requirements. Design strategies. Add features. Only target has. Remove features. Off-target needs. Modify geometry. Match target only. Exploit unique interactions. Target-specific contacts. Fine-tune distances. Critical for target. Suboptimal for off-target. Case study approach. Build selective analogs. Test panel. Learn from each. Iterative refinement. Guide design. Multi-target selectivity. Optimize for multiple targets. Against multiple off-targets. Complex optimization. Trade-offs possible. Acceptable balance needed. Pharmacophore is map. Selectivity is navigation.
Screening de selectividad
Selectividad debe medirse. Early screening. Key off-targets identified. Panel testing. Safety pharmacology panel. hERG. 5-HT2B. Adrenergic receptors. Muscarinic receptors. Kinase panels. If applicable. Broad profiling. Eurofins SafetyScreen. DiscoverX KINOMEscan. Cerep. Binding panels. Functional panels. In vitro. IC50 vs target. Selectivity ratio. Fold-selectivity. Data interpretation. 10-fold minimum. Often needed. Higher better. Context dependent. Some targets. 100-fold needed. Others. 3-fold sufficient. Therapeutic window. Effect vs toxicity. Calculate margin. Safety margin. Dose projection. In vivo relevance. Off-targets may not matter. No expression in relevant tissue. High local concentration unlikely. Panel screening identifies. Potential liabilities. Prioritize investigation. Not all matter equally.
Estrategias de diseño selectivo
Design for selectivity es intentional. Structure-based design. Use structural differences. Guide modifications. Add target-specific interactions. SAR-driven optimization. Systematic exploration. Identify selective features. Combine improvements. Counter-screening guided. Test against off-target early. Avoid cross-reactive. Design away from off-target. Allosteric approach. Target unique sites. Higher inherent selectivity. Peptide length. Longer may be more selective. More contacts. More opportunity. Shorter may be less selective. Fewer discriminators. Cyclization. Lock conformation. Target-preferred shape. Off-target excluded. Unnatural aminoacidos. Novel interactions. Target-specific chemistry. Multi-parameter optimization. Balance selectivity. With potency. With PK. With other properties. Selectivity design is integrated. Not isolated effort. Part of overall optimization.
Hallazgos Clave
- La selectividad evita efectos off-target y mejora ventana terapeutica
- Las diferencias estructurales entre blanco y off-targets guian diseno
- Los sitios alostericos son menos conservados, ofreciendo mayor selectividad
- La optimizacion de farmacoforo anade features unicos al blanco
- Los panels de screening identifican liabilidades de selectividad temprano
- El diseno selectivo integra estructura, SAR y counter-screening
Más artículos en Metodología de Investigación
Más artículos en Información General
Artículos relacionados
Términos del glosario
Preguntas frecuentes
- Que fold-selectivity es necesaria?
- Depende del off-target y consecuencias. 10-fold es minimo comun. Para off-targets con toxicidad seria (hERG, 5-HT2B), se busca >100-fold. Para off-targets menores, 3-10 fold puede ser aceptable. El margen de seguridad depende de dosis terapeutica.
- Por que sitios alostericos son mas selectivos?
- Sitios ortostericos estan bajo presion evolutiva para conservar funcion, similares entre familia. Sitios alostericos tienen menos presion, mayor variabilidad entre subtipos. Mas diversidad estructural permite mas selectividad.
- Que es el panel SafetyScreen?
- Panel comercial de Eurofins que testea binding contra ~100 blancos de seguridad (receptores, canales ionicos, transportadores). Identifica interacciones off-target potenciales. Requerido o recomendado en desarrollo de farmacos.
- Como afecta longitud del peptido la selectividad?
- Peptidos mas largos tienen mas puntos de contacto, mas oportunidades para interacciones discriminativas. Peptidos cortos tienen menos informacion de especificidad. Pero peptidos largos pueden ser menos selectivos si los contactos son promiscuos.